goldman sachs: lani blockbuster-potential , page-5

prob with that line of thought is that while it looks attractive to use lani profilactically who will want it to last as long as possible without resistance ruining it's defensive potential against a more lethal strain - so logically they will recommend use for it that way only for the vulnerable and first liners/essential service persons. Either way it will still be a huge market - but can't see it taking over from vacc for the above reasons.